APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1:500-1:3000 |
1:100-1:1000 |
1:100-1:1000 |
1:100-1:500 |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
HCT116 cells with 30uM cisplatin treatment for 24hr
Predict Reactivity
Rat, Rabbit, Sheep, Bovine, Cat, Dog, Guinea pig, Pig, Rhesus Monkey(>80% identity)
PROPERTIES
Form
Liquid
Buffer
PBS, 20% Glycerol
Preservative
0.025% ProClin 300
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1.28 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Recombinant protein encompassing a sequence within the center region of human p53. The exact sequence is proprietary.
Purification
Purified by antigen-affinity chromatography.
Conjugation
Unconjugated
RRID
AB_1952339
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
tumor protein p53 , BCC7 , BMFS5 , LFS1 , P53 , TRP53
Cellular Localization
Cytoplasm , Nucleus , Endoplasmic reticulum
Background
This gene encodes tumor protein p53, which responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity. [provided by RefSeq]
Database
Research Area
DATA IMAGES
|
GTX102965 IHC-P Image
Immunohistochemical analysis of paraffin-embedded Cal27 xenograft, using p53(GTX102965) antibody at 1:500 dilution.
Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min
|
|
GTX102965 WB Image
Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with p53 antibody (GTX102965) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
|
|
GTX102965 ICC/IF Image
p53 antibody detects p53 protein at nucleus by immunofluorescent analysis. Samples: HCT 116 cells mock (left) and treated with 30 μM Cisplatin for 24 hrs (right) were fixed in 4% paraformaldehyde at RT for 15 min. Green: p53 protein stained by p53 antibody (GTX102965) diluted at 1:500. Blue: Hoechst 33342 staining. Scale bar = 10 μm.
|
|
GTX102965 IHC-P Image
p53 antibody detects p53 protein at nucleus by immunohistochemical analysis.Sample: Paraffin-embedded human breast carcinoma.p53 stained by p53 antibody (GTX102965) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min
|
|
GTX102965 WB Image
Sample (30 μg of whole cell lysate) A: HCT116 cells with mock treatment for 24 hr B: HCT116 cells with 30 μM cisplatin treatment for 24 hr 10% SDS PAGE GTX102965 diluted at 1:1000 The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
|
|
GTX102965 WB Image
Various whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with p53 antibody (GTX102965) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.
|
|
GTX102965 WB Image
Various whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with p53 antibody (GTX102965) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
|
|
GTX102965 ICC/IF Image
p53 antibody detects p53 protein at nucleus by immunofluorescent analysis.Sample: A431 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: p53 stained by p53 antibody (GTX102965) diluted at 1:500.Red: phalloidin, a cytoskeleton marker, diluted at 1:200.
|
|
GTX102965 ChIP assay Image
p53 antibody immunoprecipitates p53 protein-DNA complex in ChIP experiments. ChIP Sample: HCT116 whole cell lysate/extract treated with CPT 500nM for 6hr A. 5 μg preimmune rabbit IgG B. 5 μg of p53 antibody (GTX102965) The precipitated DNA was detected by PCR with primer set targeting to p21 promoter.
|
|
GTX102965 IP Image
Immunoprecipitation of p53 protein. HCT116 lysates with 30uM cisplatin treatment for 24 hours were subjected to immunoprecipitation using (B) normal rabbit IgG or (C) 2.5 ug of anti-p53 antibody (GTX102965). (A) Input, 20ug of HCT116 lysates. The precipitated protein was detected by GTX102965 diluted at 1:10000. EasyBlot anti-Rabbit IgG Kit (GTX225856-01) was used in Western blot.
|
|
GTX102965 WB Image
The data was published in the journal Cancer Cell Int in 2020.PMID: 31920463
|
|
GTX102965 WB Image
The data was published in the journal Front Pharmacol in 2017.PMID: 29326587
|
REFERENCE
REVIEW
p53 antibody
Cat. No. GTX102965
Rating
|
|
( Average 4.7 based on 3 users reviews)
|
Application
Western Blot(WB)
|
|
( Average 4.5 based on 2 users reviews)
|
IHC (Paraffin sections)(IHC-P)
|
|
( Average 5 based on 1 users reviews)
|
Date :
Anonymous submitted on 21-Oct-2020
Application Tested :
IHC-P
Sample Species :
Hu
Sample :
breast cancer tissue
Fixation :
Citrate buffer, 0.3°C
Primary Antibody :
1:500, 4°C, 16Hr
Date :
Anonymous submitted on 13-Oct-2020
Application Tested :
WB
Sample Species :
Hu
Sample :
HepG2 cells
Amount used :
20 μg
Blocking :
5% non-fat milk in TBST, 22°C, 0.5Hr
Primary Antibody :
1:2000, 22°C, 18Hr
Lane Description :
Lane 1: Untreated HepG2 cells
Lane 2: 1 μM Doxorubicin for 6hr
Lane 3: Untreated HepG2 cells
Lane 4: 5 nM Actinomycin D for 6hr
Date :
Anonymous submitted on 28-Oct-2011
Application Tested :
WB
Sample Species :
Hu
Sample :
HUVEC cells
Amount used :
45μg
Blocking :
5% skin-milk, 25°C, 1Hr
Primary Antibody :
1:1000, 4°C, 16Hr